StratDeck

Two stocks in Healthcare

AbbVie vs Danaher: profit, growth, debt and price compared

AbbVie is stronger on 4 of 6 figures: sales growth, price for its expected profit, dividend and price trend. Danaher is stronger on 2: profit margin and analysts' view.

Figures as of 18 November 2026SEC EDGARYahoo Finance

Save both stocks to your watchlist and revisit their latest fundamentals.

AbbVie and Danaher side by side
AbbVieABBVDanaherDHR
Net margin15.7%Stronger: 16.9%
Revenue growth, past yearStronger: +10.32%+8.28%
Debt to equity—51.8%
Forward P/EStronger: 17.6×24.5×
Dividend yieldStronger: 2.42%0.71%
AnalystsBuy · 26Stronger: Strong buy · 21
From its 200-day averageStronger: +15.5%+9.3%

Share price over the past year

  • AbbVie+22.3%
  • Danaher+1.4%

18 Nov 202518 Nov 2026

AbbVie or Danaher: which is stronger?

  • DHR

    Which is more profitable?

    Danaher keeps more of each sale as profit: 16.9% against 15.7%.

  • ABBV

    Which is growing its sales faster?

    AbbVie is growing its sales faster: +10.32% over the past year, against +8.28%.

  • ABBV

    Which costs less for the profit it is expected to make?

    AbbVie costs less for the profit it is expected to make: 17.6× its forward earnings, against 24.5×.

  • ABBV

    Which pays more in dividends?

    AbbVie pays more back in dividends for what a share costs: 2.42% a year, against 0.71%.

  • DHR

    Which do analysts rate higher?

    Analysts are warmer on Danaher: Strong buy, against Buy for AbbVie.

  • ABBV

    Which is in the stronger price trend?

    AbbVie's price is in the stronger trend: 15.5% above its 200-day average, against 9.3% above.

What each company does

ABBVAbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.

Reports results on 3 February 2027

DHRDanaher

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.

Reports results on 27 January 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every US healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.